Frontier pharma first in class innovation in hematological cancers cytokine signaling

Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline

“The American Cancer Society (ACS) predicts that in 2017 there will be almost 173,000 new cases of leukemia, lymphoma and myeloma, with lymphomas the most prevalent.�

Summary The American Cancer Society (ACS) predicts that in 2017 there will be almost 173,000 new cases of leukemia, lymphoma and myeloma, with lymphomas the most prevalent. Due to a degree of crossover between hematological malignancies in terms of their underlying pathophysiology, it is not uncommon for products being developed for this therapy area to have developmental programs testing them across multiple indications.

The report assesses versatile and first-in-class innovation in the hematological cancer pipeline, highlighting key trends in first-in-class product distribution.

Read Complete Report with TOC @ http://www.radiantinsights.com/research/frontierpharma--first-in-class-innovation-in-hematological-cancers

Follow Us:

Analysis reveals that the hematological cancer pipeline is among the most innovative in the industry, with 477 first-in-class products.

Over the past 15 years, the treatment of hematological malignancies has changed significantly, thanks to the development of targeted therapies. These developments have been based on the growing understanding of the signaling pathways involved in disease pathogenesis. A notable example is the approval of Rituxan in 1997, which is used to treat multiple types of hematological malignancies, including Non-Hodgkin’s lymphoma. Analysis indicates that the current pipeline is following this trend of focusing on innovative, targeted therapies.

The first-in-class targets in the pipeline are numerous and varied. Cytokine signaling targets are the most common, with a total of 548 across all stages of development, followed by kinases. These target categories account for the majority of targeted immunotherapies, which are the primary focus of current development activity within oncology. The other target families have far fewer first-in-class and versatile first-in-class products, reflecting the strong interest and potential versatility of cancer immunotherapies.

Related reports by Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare Scope - With 1,474 products in active development, the pipeline is considerably large. How will pipeline innovation affect the future hematological cancer market?

- There are 477 first-in-class products in the hematological cancer pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?

- The majority of first-in-class products were identified to be in development for multiple indications. Are versatile products likely to play a key role in the future treatment of hematological cancer?

- Analysis of the history of strategic consolidations revealed an increasing amount of deal activity and a large number of first-in-class products not yet involved in any deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Reasons to buy - Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.

Follow Us:

- Visualize the composition of the hematological cancers market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed.

This knowledge allows a competitive understanding of gaps in the current market.

- Analyze the hematological cancers pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating hematological cancers.

- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.

- Understand the level of versatility across the pipeline and within each molecular target. Assess the pipeline activity of each versatile first-in-class product and the indications that they are being developed for.

- Identify commercial opportunities in the hematological cancers deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of hematological cancer therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Download sample Copy of This Report at: http://www.radiantinsights.com/research/frontier-pharma--first-in-class-innovationin-hematological-cancers/request-sample Table of Contents 1 Table of Contents 2 1.1 List of Tables 3 1.2 List of Figures 3

2 Executive Summary 5 2.1 Large Therapy Area with a High Degree of Pathophysiological Crossover 5 2.2 High Degree of First-in-Class Programs and Program Versatility in a Strong Pipeline 5 2.3 Sharp Increase in Deal Activity in Recent Years 5

3 The Case for Innovation in the Hematological Cancer Market 6 3.2 Diversification of Molecular Targets 7

Follow Us:

3.3 Innovative First-in-Class Product Developments Remain Attractive 8 3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8 3.5 Sustained Innovation 9 3.6 GBI Research Report Guidance 9

4 Clinical and Commercial Landscape 10 4.1 Disease Overview 10 4.2 Symptoms 10 4.3 Diagnosis 10 4.3.1 Leukemia 10 4.3.2 Lymphoma 11 4.3.3 Myeloma 12 Read Complete Report with TOC @ http://www.radiantinsights.com/research/frontierpharma--first-in-class-innovation-in-hematological-cancers 4.4 Etiology 12 4.4.1 Leukemia 12 4.4.2 Lymphoma 12 4.4.3 Myeloma 12 4.5 Pathophysiology 13 4.5.1 Leukemia 13 4.5.2 Lymphoma 14 4.5.3 Myeloma 16 4.6 Epidemiology 17 4.6.1 Leukemia 17 4.6.2 Lymphoma 18 4.6.3 Myeloma 18

Follow Us:

4.7 Treatment 18 4.7.1 Surgery and Radiation Therapy 19 4.7.2 Stem-Cell Transplantation 19 4.7.3 Pharmacotherapy 20 4.8 Overview of Marketed Products 21 4.9 Current Unmet Need in the Hematological Cancer Market 22

5 Pipeline Landscape Assessment 24 5.1 Hematological Cancers Pipeline Overview 24 5.1.1 Pipeline Development Landscape 24 5.1.2 Molecular Targets in the Pipeline 25 5.1.3 Comparative Distribution of Programs between the Hematological Cancer Market and Pipeline

by Molecular Target 26 5.2 First-in-Class and Versatile Programs 26 5.2.1 First-in-Class Hematological Cancers Programs by Phase, Molecule Type and Molecular Target 26 5.2.2 Versatility of First-in-Class Pipeline Programs 30

6 Signaling Network and Innovation Alignment within Hematological Cancers 39 6.1 Complexity of Signaling Networks in Hematological cancer 39 6.2 Signaling Pathways and First-in-Class Molecular Target Integration 39 6.3 First-in-Class Matrix Assessment 40

7 First-in-Class Target Evaluation 45 7.1 Pipeline Programs Targeting Neurogenic Locus Notch Homolog Protein 1 45 7.1.1 Overview of Pipeline Programs Targeting Neurogenic Locus Notch Homolog Protein 1 46

Follow Us:

About Radiant Insights, Inc: Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Contact Details: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc 28 2nd Street, Suite 3036, San Francisco, CA 94105, United States Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Web: http://www.radiantinsights.com/ Visit Our Blog: http://www.radiantinsightsinc.blogspot.com

Follow Us: